Export 22 results:
Author [ Title(Desc)] Type Year
Filters: Author is Enama, Mary E  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
C
J. E. Ledgerwood, DeZure, A. D., Stanley, D. A., Coates, E. E., Novik, L., Enama, M. E., Berkowitz, N. M., Hu, Z., Joshi, G., Ploquin, A., Sitar, S., Gordon, I. J., Plummer, S. A., Holman, L. S. A., Hendel, C. S., Yamshchikov, G., Roman, F., Nicosia, A., Colloca, S., Cortese, R., Bailer, R. T., Schwartz, R. M., Roederer, M., Mascola, J. R., Koup, R. A., Sullivan, N. J., and Graham, B. S., “Chimpanzee Adenovirus Vector Ebola Vaccine.”, N Engl J Med, vol. 376, no. 10, pp. 928-938, 2017.
D
J. E. Ledgerwood, Wei, C. - J., Hu, Z., Gordon, I. J., Enama, M. E., Hendel, C. S., McTamney, P. M., Pearce, M. B., Yassine, H. M., Boyington, J. C., Bailer, R., Tumpey, T. M., Koup, R. A., Mascola, J. R., Nabel, G. J., and Graham, B. S., “DNA priming and influenza vaccine immunogenicity: two phase 1 open label randomised clinical trials.”, Lancet Infect Dis, vol. 11, no. 12, pp. 916-24, 2011.
J. E. Ledgerwood, Bellamy, A. R., Belshe, R., Bernstein, D. I., Edupuganti, S., Patel, S. M., Renehan, P., Zajdowicz, T., Schwartz, R., Koup, R., Bailer, R. T., Yamshchikov, G. V., Enama, M. E., Sarwar, U., Larkin, B., and Graham, B. S., “DNA priming for seasonal influenza vaccine: a phase 1b double-blind randomized clinical trial.”, PLoS One, vol. 10, no. 5, p. e0125914, 2015.
B. S. Graham, Enama, M. E., Nason, M. C., Gordon, I. J., Peel, S. A., Ledgerwood, J. E., Plummer, S. A., Mascola, J. R., Bailer, R. T., Roederer, M., Koup, R. A., and Nabel, G. J., “DNA vaccine delivered by a needle-free injection device improves potency of priming for antibody and CD8+ T-cell responses after rAd5 boost in a randomized clinical trial.”, PLoS One, vol. 8, no. 4, p. e59340, 2013.
K. V. Houser, Yamshchikov, G. V., Bellamy, A. R., May, J., Enama, M. E., Sarwar, U., Larkin, B., Bailer, R. T., Koup, R., Paskel, M., Subbarao, K., Anderson, E., Bernstein, D. I., Creech, B., Keyserling, H., Spearman, P., Wright, P. F., Graham, B. S., and Ledgerwood, J. E., “DNA vaccine priming for seasonal influenza vaccine in children and adolescents 6 to 17 years of age: A phase 1 randomized clinical trial.”, PLoS One, vol. 13, no. 11, p. e0206837, 2018.
H
U. N. Sarwar, Novik, L., Enama, M. E., Plummer, S. A., Koup, R. A., Nason, M. C., Bailer, R. T., McDermott, A. B., Roederer, M., Mascola, J. R., Ledgerwood, J. E., and Graham, B. S., “Homologous boosting with adenoviral serotype 5 HIV vaccine (rAd5) vector can boost antibody responses despite preexisting vector-specific immunity in a randomized phase I clinical trial.”, PLoS One, vol. 9, no. 9, p. e106240, 2014.
P
A. T. Catanzaro, Koup, R. A., Roederer, M., Bailer, R. T., Enama, M. E., Moodie, Z., Gu, L., Martin, J. E., Novik, L., Chakrabarti, B. K., Butman, B. T., Gall, J. G. D., C King, R., Andrews, C. A., Sheets, R., Gomez, P. L., Mascola, J. R., Nabel, G. J., and Graham, B. S., “Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 candidate vaccine delivered by a replication-defective recombinant adenovirus vector.”, J Infect Dis, vol. 194, no. 12, pp. 1638-49, 2006.
B. S. Graham, Koup, R. A., Roederer, M., Bailer, R. T., Enama, M. E., Moodie, Z., Martin, J. E., McCluskey, M. M., Chakrabarti, B. K., Lamoreaux, L., Andrews, C. A., Gomez, P. L., Mascola, J. R., and Nabel, G. J., “Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 DNA candidate vaccine.”, J Infect Dis, vol. 194, no. 12, pp. 1650-60, 2006.
M. C. Crank, Gordon, I. J., Yamshchikov, G. V., Sitar, S., Hu, Z., Enama, M. E., Holman, L. S. A., Bailer, R. T., Pearce, M. B., Koup, R. A., Mascola, J. R., Nabel, G. J., Tumpey, T. M., Schwartz, R. M., Graham, B. S., and Ledgerwood, J. E., “Phase 1 study of pandemic H1 DNA vaccine in healthy adults.”, PLoS One, vol. 10, no. 4, p. e0123969, 2015.
A. T. Catanzaro, Roederer, M., Koup, R. A., Bailer, R. T., Enama, M. E., Nason, M. C., Martin, J. E., Rucker, S., Andrews, C. A., Gomez, P. L., Mascola, J. R., Nabel, G. J., and Graham, B. S., “Phase I clinical evaluation of a six-plasmid multiclade HIV-1 DNA candidate vaccine.”, Vaccine, vol. 25, no. 20, pp. 4085-92, 2007.
M. E. Enama, Ledgerwood, J. E., Novik, L., Nason, M. C., Gordon, I. J., Holman, L. S., Bailer, R. T., Roederer, M., Koup, R. A., Mascola, J. R., Nabel, G. J., and Graham, B. S., “Phase I randomized clinical trial of VRC DNA and rAd5 HIV-1 vaccine delivery by intramuscular (i.m.), subcutaneous (s.c.) and intradermal (i.d.) administration (VRC 011).”, PLoS One, vol. 9, no. 3, p. e91366, 2014.
J. E. Ledgerwood, Zephir, K., Hu, Z., Wei, C. - J., Chang, L., Enama, M. E., Hendel, C. S., Sitar, S., Bailer, R. T., Koup, R. A., Mascola, J. R., Nabel, G. J., and Graham, B. S., “Prime-boost interval matters: a randomized phase 1 study to identify the minimum interval necessary to observe the H5 DNA influenza vaccine priming effect.”, J Infect Dis, vol. 208, no. 3, pp. 418-22, 2013.
R. A. Koup, Roederer, M., Lamoreaux, L., Fischer, J., Novik, L., Nason, M. C., Larkin, B. D., Enama, M. E., Ledgerwood, J. E., Bailer, R. T., Mascola, J. R., Nabel, G. J., and Graham, B. S., “Priming immunization with DNA augments immunogenicity of recombinant adenoviral vectors for both HIV-1 specific antibody and T-cell responses.”, PLoS One, vol. 5, no. 2, p. e9015, 2010.
R. A. Seder, Chang, L. - J., Enama, M. E., Zephir, K. L., Sarwar, U. N., Gordon, I. J., Holman, L. S. A., James, E. R., Billingsley, P. F., Gunasekera, A., Richman, A., Chakravarty, S., Manoj, A., Velmurugan, S., Li, M. L., Ruben, A. J., Li, T., Eappen, A. G., Stafford, R. E., Plummer, S. H., Hendel, C. S., Novik, L., Costner, P. J. M., Mendoza, F. H., Saunders, J. G., Nason, M. C., Richardson, J. H., Murphy, J., Davidson, S. A., Richie, T. L., Sedegah, M., Sutamihardja, A., Fahle, G. A., Lyke, K. E., Laurens, M. B., Roederer, M., Tewari, K., Epstein, J. E., B Sim, K. Lee, Ledgerwood, J. E., Graham, B. S., and Hoffman, S. L., “Protection against malaria by intravenous immunization with a nonreplicating sporozoite vaccine.”, Science, vol. 341, no. 6152, pp. 1359-65, 2013.
S
U. N. Sarwar, Costner, P., Enama, M. E., Berkowitz, N., Hu, Z., Hendel, C. S., Sitar, S., Plummer, S., Mulangu, S., Bailer, R. T., Koup, R. A., Mascola, J. R., Nabel, G. J., Sullivan, N. J., Graham, B. S., and Ledgerwood, J. E., “Safety and immunogenicity of DNA vaccines encoding Ebolavirus and Marburgvirus wild-type glycoproteins in a phase I clinical trial.”, J Infect Dis, vol. 211, no. 4, pp. 549-57, 2015.
H. Kibuuka, Berkowitz, N. M., Millard, M., Enama, M. E., Tindikahwa, A., Sekiziyivu, A. B., Costner, P., Sitar, S., Glover, D., Hu, Z., Joshi, G., Stanley, D., Kunchai, M., Eller, L. Anne, Bailer, R. T., Koup, R. A., Nabel, G. J., Mascola, J. R., Sullivan, N. J., Graham, B. S., Roederer, M., Michael, N. L., Robb, M. L., and Ledgerwood, J. E., “Safety and immunogenicity of Ebola virus and Marburg virus glycoprotein DNA vaccines assessed separately and concomitantly in healthy Ugandan adults: a phase 1b, randomised, double-blind, placebo-controlled clinical trial.”, Lancet, vol. 385, no. 9977, pp. 1545-54, 2015.
C. Carter, Houser, K. V., Yamshchikov, G. V., Bellamy, A. R., May, J., Enama, M. E., Sarwar, U., Larkin, B., Bailer, R. T., Koup, R., Chen, G. L., Patel, S. M., Winokur, P., Belshe, R., Dekker, C. L., Graham, B. S., and Ledgerwood, J. E., “Safety and immunogenicity of investigational seasonal influenza hemagglutinin DNA vaccine followed by trivalent inactivated vaccine administered intradermally or intramuscularly in healthy adults: An open-label randomized phase 1 clinical trial.”, PLoS One, vol. 14, no. 9, p. e0222178, 2019.
L. - J. Chang, Dowd, K. A., Mendoza, F. H., Saunders, J. G., Sitar, S., Plummer, S. H., Yamshchikov, G., Sarwar, U. N., Hu, Z., Enama, M. E., Bailer, R. T., Koup, R. A., Schwartz, R. M., Akahata, W., Nabel, G. J., Mascola, J. R., Pierson, T. C., Graham, B. S., and Ledgerwood, J. E., “Safety and tolerability of chikungunya virus-like particle vaccine in healthy adults: a phase 1 dose-escalation trial.”, Lancet, vol. 384, no. 9959, pp. 2046-52, 2014.
J. Parrino, McCurdy, L. H., Larkin, B. D., Gordon, I. J., Rucker, S. E., Enama, M. E., Koup, R. A., Roederer, M., Bailer, R. T., Moodie, Z., Gu, L., Yan, L., and Graham, B. S., “Safety, immunogenicity and efficacy of modified vaccinia Ankara (MVA) against Dryvax challenge in vaccinia-naïve and vaccinia-immune individuals.”, Vaccine, vol. 25, no. 8, pp. 1513-25, 2007.
J. E. Martin, Louder, M. K., Holman, L. S. A., Gordon, I. J., Enama, M. E., Larkin, B. D., Andrews, C. A., Vogel, L., Koup, R. A., Roederer, M., Bailer, R. T., Gomez, P. L., Nason, M., Mascola, J. R., Nabel, G. J., and Graham, B. S., “A SARS DNA vaccine induces neutralizing antibody and cellular immune responses in healthy adults in a Phase I clinical trial.”, Vaccine, vol. 26, no. 50, pp. 6338-43, 2008.
T
J. P. Casazza, Bowman, K. A., Adzaku, S., Smith, E. C., Enama, M. E., Bailer, R. T., Price, D. A., Gostick, E., Gordon, I. J., Ambrozak, D. R., Nason, M. C., Roederer, M., Andrews, C. A., Maldarelli, F. M., Wiegand, A., Kearney, M. F., Persaud, D., Ziemniak, C., Gottardo, R., Ledgerwood, J. E., Graham, B. S., and Koup, R. A., “Therapeutic vaccination expands and improves the function of the HIV-specific memory T-cell repertoire.”, J Infect Dis, vol. 207, no. 12, pp. 1829-40, 2013.
W
J. E. Ledgerwood, Pierson, T. C., Hubka, S. A., Desai, N., Rucker, S., Gordon, I. J., Enama, M. E., Nelson, S., Nason, M., Gu, W., Bundrant, N., Koup, R. A., Bailer, R. T., Mascola, J. R., Nabel, G. J., and Graham, B. S., “A West Nile virus DNA vaccine utilizing a modified promoter induces neutralizing antibody in younger and older healthy adults in a phase I clinical trial.”, J Infect Dis, vol. 203, no. 10, pp. 1396-404, 2011.